Simulations Plus today announced the addition of Sandra Suarez-Sharp as Vice President, Regulatory Affairs to lead the new Regulatory Strategies team.
20-year FDA Master Reviewer will advise the planning of drug development programs with sponsor companies
Generalized PBPK Model for Evaluation of Inhalation Exposure of Volatile Organic Compounds
Physiologically based pharmacokinetic modeling (PBPK) is a valuable tool to evaluate inhalation exposure of volatile organic compounds (VOCs).
Quantitative Systems Toxicology (DILIsym) Modeling of the Acetaminophen Cellular Pathways for Liver Toxicity Supports that Acetaminophen is Not a Carcinogenic Hazard in Humans
Acetaminophen has a long history of safe use at therapeutic doses, but can cause liver injury at very high doses.
Synergy Between Two Mechanisms of Action Contributes to Species Differences in the Liver Safety Profile for PF-04895162
PF-04895162 (ICA-105665), a drug in development for the treatment of epilepsy, was terminated after transaminase elevations (up to grade...
Quantitative Systems Toxicology Modeling of Cisplatin Nephrotoxicity Using in vitro Assays of Proximal Tubule Epithelial Cells for Mechanistic Toxicity Pathways
Cisplatin-induced nephrotoxicity results in acute kidney injury (AKI) and is caused by various cellular mechanisms, including...
Using in silico-in vitro to in vivo Extrapolation (IS-IVIVE) to Predict the Oral Dose Required to Activate the Aryl Hydrocarbon Receptor (AhR)
Activation of AhR can have toxic effects on mammalian hosts
Putting deep learning in perspective for pest management scientists
‘Deep learning’ is causing rapid technological changes in many fields of science, and conjectures about its potential for...
Feature of the week #81: Efficient alternative implementation for common equations including delays
Delayed differential equations (DDEs) can be implemented in Mlxtran language using the "delay" function.
In vitro – In vivo correlation in the development of oral drug formulation: A screenshot of the last two decades
In vitro – in vivo correlation (IVIVC) allows prediction of the in vivo performance of a pharmaceutical product based on its in vitro...
Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
Emerging drug resistance and high-attrition rates in early and late stage drug development necessitate accelerated development of antimalarial compounds.
March 2020 GastroPlus Newsletter
Since last month’s newsletter, the world has become Coronavirus conscious.
Understanding the Oral Absorption of Irbesartan Using Biorelevant Dissolution Testing and PBPK Modeling
Poorly soluble weak bases form a significant proportion of the drugs available in the market thereby making it imperative to...
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease
Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that suffer from neurodegenerative disorders ...
5 Reasons to Choose Simulations Plus Services for your Drug Discovery and Development Needs
Throughout the drug discovery process, companies need to eliminate poor drug candidates early to avoid costly studies and dead ends.
GastroPlus® Tutorial: Getting Started with GastroPlus – A Software Introduction
Maxime LeMerdy introduces GastroPlus 9.7 interface and walks you through each tab.
Feature of the week #80: Understanding and using the Monolix ‘proposal’
Monolix is able to use the individual parameters of the current run to pre-test several covariate, correlation and error models
Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs using PBBM Modeling: Industry Case Studies
Acid-reducing agents (ARA) such as antacids, histamine H2-receptor antagonists, and proton pump inhibitors are widely prescribed in several disease states.
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling
Oseltamivir is a neuraminidase inhibitor widely used to treat and prevent influenza A and B infections, although its safety and pharmacokinetics have not been evaluated in patients with severe hepatic impairment.
Identification of potential inhibitors of human methionine aminopeptidase (type II) for cancer therapy: Structure-based virtual screening, ADMET prediction and molecular dynamics studies
Methionine Aminopeptidases MetAPs are divalent-cofactor dependent enzymes that are responsible for the cleavage of the initiator...